LILRB4 and cancer: In conclusion, we have identified LILRB4 as a potential new target of tumor immunotherapy in solid tumors, effective either as monotherapy or potentially in combination with antibodies targeting T cells, and further studies could lead to development of novel immunotherapy drug for the treatment of cancer.